Phathom Pharmaceuticals, Inc. Announces Management Changes
December 02, 2019 at 08:30 am EST
Share
Phathom Pharmaceuticals, Inc. announced multiple executive appointments. As previously announced as part of the Company's
succession plan, Terrie Curran, former President of the Global Inflammation and Immunology (I&I) Franchise at Celgene, now joins Phathom as Chief Executive Officer. Founding CEO David Socks transitions to interim Chief Financial Officer and remains a member of the Board of Directors. In addition to Ms. Curran, also joining the Phathom leadership team are Eckhard Leifke, MD, as Chief Medical Officer; Joseph Hand, JD, as Chief Administrative Officer; and Larry Miller, JD, as General Counsel. Phathom also announced that Asit Parikh, MD, PhD has replaced Chris Slavinsky on the Company's Board of Directors. Ms. Curran has more than 20 years of experience in the biopharmaceutical industry. She has served as President, Global Inflammation and Immunology (I&I) Franchise and as a member of the Executive Committee at Celgene Corporation since 2017. Dr. Leifke joins Phathom from Omeros where he served as Chief Medical Officer. Prior to Omeros, he held executive roles at Sanofi, including Global Head/Vice President of Early Project & External Opportunities - Cardiovascular and Metabolism and Global Head/Vice President of Late Stage Development - Diabetes. Mr. Hand joins Phathom from Celgene, where he most recently served as Executive Vice President, Global Human Resources and Corporate Services and a member of its Executive Committee. In that capacity, he was responsible for all employee-related activities including talent development, recruiting, and compensation and benefits. Mr. Miller joins Phathom as General Counsel from Cyclerion Therapeutics where he served as General Counsel and Secretary. Prior to Cyclerion, he served as Senior Vice President, General Counsel and Secretary of Blue Buffalo where he led all legal activities including those related to the $8 billion acquisition by General Mills. In addition to the executive appointments, Dr. Parikh joins Phathom's Board of Directors as Chris Slavinsky steps down following his departure from Takeda to join Prometheus Biosciences. Dr. Parikh is currently Senior Vice President and Head of the Gastroenterology Therapeutic Area Unit at Takeda.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Companyâs pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.